

### Final Appraisal Recommendation Advice No: 2216 – July 2016

**Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide  
(Genvoya<sup>®</sup>▼)  
150 mg/150 mg/200 mg/10 mg tablets**

**Limited submission by Gilead Sciences Ltd**

#### Recommendation of AWMSG

**Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (Genvoya<sup>®</sup>▼) is recommended as an option for use within NHS Wales for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus 1 (HIV-1) without any known mutations associated with resistance to the integrase inhibitor class, emtricitabine or tenofovir.**

**This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price.**

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 2248), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Marketing authorisation holder on first issue	Gilead Sciences Ltd
Date of first issue	July 2016
Last reviewed	July 2019

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 2216:  
Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (Genvoya<sup>®</sup>▼)  
150 mg/150 mg/200 mg/10 mg tablets.  
July 2016.